EV046135

EV046135 is a human monoclonal antibody developed by Evec, Inc. that acts as a neutralizing agent against human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). The antibody was identified using Evec's proprietary technology, which involves the generation of human monoclonal antibodies from EBV-immortalized B cells. EV046135 is designed to target viral surface antigens to prevent viral entry and infection in the respiratory tract. While it was specifically identified in earlier company communications, it appears to be part of a broader hMPV/RSV antibody program within Evec's pipeline, which has explored potential licensing partnerships with larger pharmaceutical companies.